Home Health Equipment Rental (NAICS 532283): An Investor's Primer

U.S. industry primer for general investors — public and private. All figures U.S.; core federal statistics are 2022–2023.

---

1. Overview

When a patient goes home from the hospital on oxygen, a CPAP (continuous positive airway pressure) machine for sleep apnea, a home ventilator, a hospital bed, or a wheelchair, a company delivers, sets up, and services that equipment — and bills an insurer, usually Medicare, a fixed amount each month. That business is NAICS 532283, Home Health Equipment Rental, part of the broader durable medical equipment (DME) or home medical equipment (HME) trade.

The single most important thing to understand up front: this industry lives inside the Census Bureau's "Real Estate and Rental and Leasing" sector, but it is not a real-estate business. There are no real estate investment trusts (REITs) here, and the usual property toolkit — net operating income, capitalization rates, funds from operations — does not apply (Section 5 explains why, and defines those terms). What looks like "rent" is a government-set reimbursement rate. The industry's fortunes are driven by Medicare payment policy, not property values or interest rates. That reframing runs through everything below.

Why an investor cares. Demand is powered by an aging population and chronic disease, and it is largely non-discretionary — people need oxygen in a recession too. That makes revenue unusually stable. The catch is that a government agency, the Centers for Medicare & Medicaid Services (CMS), sets the prices, and can cut them faster than demographics can lift volume. It is a demographic compounder wrapped in regulatory risk.

Public vs. private ways in. Public-market investors can own a handful of operating companies (AdaptHealth, Accendra/Apria, Quipt, Viemed, Inogen; Lincare only indirectly through Linde). Private investors buy, build, or lend to the thousands of small regional suppliers that make up the industry's long tail. Both are covered in Sections 4 and 10.

---

2. What it is, and what it isn't

Scope. NAICS 2022 defines 532283 as establishments primarily engaged in renting home-type health and invalid equipment — wheelchairs, hospital beds, oxygen tanks, walkers, crutches [1]. In practice the revenue core today is home respiratory (oxygen concentrators, home ventilators, CPAP/bilevel sleep devices) plus mobility and hospital-bed rental.

Adjacent codes it excludes [1]:

• 621610 — Home Health Care Services (skilled nursing/therapy that happens to include equipment).
• 423450 — Medical equipment wholesalers and 456110/456199 — retailers (companies that mainly sell rather than rent).
• 532490 — non-home medical/industrial equipment rental; 339112/339113 — device manufacturing.
• The real-estate lessor codes (531110 residential, 531120 non-residential) and the intangible-licensing code (533110) — none of which describe this business.

Why that matters for the numbers. NAICS classifies each location by its primary activity. The big national players earn their revenue from a blend of equipment rental, outright equipment sales, and recurring consumable "resupply" (CPAP masks, oxygen tubing, diabetes sensors) — so large parts of their revenue are coded in retail, wholesale, or home-health-services codes, not in 532283. As a result the federal 532283 figure materially understates the real home-DME economy. A useful reality check: Medicare fee-for-service alone spent about $7.5 billion on DME in 2022 [5] — more than the entire Census 532283 industry's revenue — because DME spending is spread across several NAICS codes and payers. Read the size figures below as "the rental-classified core," not "the whole DME market."

Ownership mix. A barbell: a few large national platforms (one public pure-play, one industrial-conglomerate subsidiary, and private-equity-controlled operators) sitting atop thousands of small, often family-owned, single-location suppliers. There are no publicly traded "landlord" vehicles; you own operating companies or you own private ones.

---

3. How big it is

Core federal statistics (our ingested ground truth):

Two honest caveats on these figures:

1. The Herfindahl-Hirschman Index (HHI, the standard single-number concentration gauge) is suppressed in the source data — we do not have it, and I will not estimate one. But the concentration ratios speak for themselves: the four largest firms take about two-thirds of the narrow industry's revenue (65.8%), and the top 50 take roughly six-sevenths (85.8%). That is a heavily top-weighted industry with a fragmented tail beneath it. (This 2022 CR4 is up from an estimated ~53% in 2017 per an SBA special tabulation — corroborating the consolidation story, though that older figure is a single-source estimate.) [2]
2. The classification undercount runs the other way from most real-estate industries. In residential real estate, Census business statistics undercount because most rental units are owned by small individual landlords and pass-throughs the surveys miss. Here the undercount comes from primary-activity coding — the national operators' rental revenue is scattered across retail/wholesale/home-health codes. A small self-employed tail also exists (Census counted a few hundred nonemployer operators with only tens of millions in receipts). Either way, treat $5.89 billion as a floor on the rental-classified activity, not a ceiling on the DME opportunity.

The consolidation signature. Comparing the 2017 and 2022 Economic Censuses (same methodology), revenue rose roughly +44% while the number of firms fell ~14% and establishments fell ~27% — fewer, larger operators generating far more revenue each. That is the fingerprint of an industry consolidating under reimbursement pressure (Section 8) [2].

"Asset stock." There is no authoritative federal count of the nationwide installed fleet of concentrators, CPAP units, ventilators, beds, and wheelchairs across all payers — a genuine data gap. The better proxies are company-level patient counts: AdaptHealth alone serves about 4.3 million patients a year across ~640 locations; Viemed reported 12,259 ventilator and 34,528 CPAP/bilevel patients at year-end 2025 [9][13]. The deployed "asset stock" is millions of devices, refreshed continuously.

---

4. The investable universe

There are no REITs and no pure "rental landlord" equities. Exposure is via operating companies (public or private). Public names are small- to mid-cap operating companies, not dividend/yield vehicles — none is a meaningful income play, so the relevant metrics are enterprise value to EBITDA and free cash flow, not dividend yield (Section 5).

Public and publicly accessible operators (latest reported fiscal year):

*AdaptHealth revenue from its FY2025 10-K [9]; ~$1.3B market cap is a single-source mid-2026 estimate.

Largest private platform. Rotech Healthcare operates 300+ locations in 45 states, having integrated 65+ acquisitions in four years; it refinanced $725 million of secured credit in late 2025, signaling private-equity-style leverage. Owens & Minor agreed to buy it for $1.36 billion in 2024 but the deal was terminated in mid-2025 (see Section 8), so it remains private [10][15].

The long tail. Beneath the leaders sit thousands of small operators — regional respiratory companies, family-owned DME dealers, hospital-affiliated units, and private-equity buy-and-build platforms. With the whole industry averaging only ~$11 million of revenue per firm ($5.89B ÷ 521), and the SBA "small business" line at $41 million, the overwhelming majority of firms are, by the government's own definition, small businesses [2][4].

---

5. How the money works

First, why the real-estate playbook doesn't apply — with the terms defined so you can see the mismatch:

• A REIT (real estate investment trust) is a property-owning company that must distribute ~90% of taxable income to shareholders and pays little corporate tax; investors value it on FFO/AFFO (funds from operations / adjusted funds from operations) — net income with real-estate depreciation added back — and on price-to-NAV (net asset value). NOI (net operating income) is property rent minus property operating cost, and a cap rate (capitalization rate) converts that NOI into a property value.
• None of this fits 532283. These are ordinary taxable operating companies with no distribution requirement. Their depreciating machines are a real economic cost of earning revenue — adding depreciation back (as FFO does for buildings) would overstate earnings, not correct them. So investors use EBITDA (earnings before interest, taxes, depreciation, and amortization), free cash flow (FCF), net leverage, and enterprise-value-to-EBITDA (EV/EBITDA) multiples — the metrics for an operating company, not a landlord.

The real model is a reimbursement-driven rental-and-resupply annuity:

(a) Regulated "rent." Medicare pays for most DME under a fee schedule at 80% of the lower of the supplier's charge or the schedule amount, with the patient responsible for 20% coinsurance [5]. The payment structure is the heart of the business:

• Capped-rental items (standard wheelchairs, hospital beds, CPAP): Medicare rents for up to 13 months, after which the patient owns the device. CPAP additionally requires the patient to demonstrate compliant use within 90 days or coverage stops [5][7].
• Oxygen: rental is capped at 36 months, after which the supplier keeps title but must keep servicing the equipment and supplying oxygen through a five-year useful life [7]. Oxygen is the archetypal long-duration annuity.

(b) The resupply annuity. Once a patient is on service, consumable resupply (masks, tubing, sensors) generates recurring, higher-margin, low-capital revenue. This is the most profitable part of the model — and the part online direct-to-consumer sellers are attacking (Section 8).

(c) "Utilization" — but not the way an equipment-rental firm means it. Traditional rental companies track time utilization (share of fleet on rent) and dollar utilization (annual rent as a % of fleet cost). HME operators rarely disclose these; the working equivalents are active billable patient census, revenue per active patient, and redeployment time. A concentrator sitting in a warehouse earns nothing; so does one placed with a patient whose paperwork isn't compliant. Utilization here is really billable-patient utilization.

(d) Capital intensity, depreciation, and residual value. Operators capitalize and depreciate their fleets. AdaptHealth reported $341 million of patient-equipment depreciation in 2025 (about 10.5% of revenue) on ~$382 million of equipment purchases, depreciating devices over roughly 13 months to five years — timelines that track the reimbursement cycles [9]. Crucially, residual/resale value is weak and is a cost to manage, not a profit center: many capped-rental assets transfer to the patient at month 13; used devices must be retrieved, disinfected, and refurbished; and recalls or new technology can strand a fleet. This is the opposite of car- or construction-equipment rental, where resale value is a profit lever.

(e) Rental-vs-ownership penetration. For the patient, "rent vs. own" is decided by Medicare's category rules, not the market. For the supplier, the prize is capital-light, long-duration streams — 36-month oxygen and ongoing resupply. Tellingly, on a consolidated basis the big platforms are more sale-and-resupply than pure rental: AdaptHealth's 2025 revenue was ~33% fixed-monthly reimbursement (rental) versus ~63% sales [9].

(f) Margins and leverage. Reported profitability clusters around 20–30% EBITDA margins (AdaptHealth ~21%; Rotech historically ~30%), with the spread driven by payer mix, route density, resupply penetration, and purchasing scale. Because prices are set externally, cost-to-serve — delivery, setup, billing, denials management — is the main lever operators actually control. These are cash-generative, moderately levered businesses (net debt around 2.5–3.0x EBITDA), financed with term loans and revolvers [9].

---

6. What drives demand

1. Aging population — the structural tailwind. The U.S. 65-and-older population reached 61.2 million in 2024 (18.0% of the country), up 13% since 2020 [16], and the oldest cohorts (heaviest equipment users) grow fastest.
2. Chronic respiratory disease. The CDC reported diagnosed COPD (chronic obstructive pulmonary disease) in 3.8% of adults in 2023 — but 8.9% of those aged 65–74 and 10.5% of those 75+ — the fifth-leading cause of death, with ~$24 billion in annual medical costs [17]. COPD drives oxygen, nebulizer, and ventilation demand.
3. Sleep apnea. A 2025 peer-reviewed model estimated 83.7 million U.S. adults had obstructive sleep apnea (OSA) in 2024 — a large, under-diagnosed population (a modeled estimate, directional, not a claims count) [18]. This underpins CPAP demand.
4. Care shifting into the home. Payers favor home care as cheaper than facility care, and patients prefer it — expanding the base for home oxygen, ventilation, beds, and monitoring.
5. Reimbursement-gated, not consumer-cyclical. Demand is largely non-discretionary; recessions barely dent it. What moves the industry is policy, not the business cycle.

---

7. Regulation

For 532283, reimbursement policy is the regulatory regime. Fair-housing, zoning, and rent-control rules are irrelevant.

• CMS fee schedules & HCPCS coding. CMS sets payment amounts by item category [5]. This is the single most important external variable in the industry.
• The DMEPOS Competitive Bidding Program. CMS can replace administratively set prices with competitively bid single payment amounts for selected products and regions (DMEPOS = durable medical equipment, prosthetics, orthotics, and supplies). The prior contracts expired December 31, 2023, opening a gap in which any enrolled supplier may bill at fee-schedule rates. CMS has announced a new round to begin no later than January 1, 2028, with registration/bidding in late 2026 and awards in 2027. Notably, the announced 2028 categories are continuous glucose monitors, insulin pumps, and urological/ostomy/brace supplies — not core home oxygen, CPAP, hospital beds, or wheelchairs [6]. That limits the near-term hit to respiratory-focused operators but re-establishes bidding as a live pricing mechanism that could later be widened. The scope and price level of future bidding rounds is the industry's biggest single regulatory swing factor.
• A live 2026 enrollment moratorium. On February 27, 2026, CMS imposed a temporary nationwide moratorium on new Medicare enrollment for specified DMEPOS supplier types (including medical-supply companies with respiratory therapists or pharmacists), applying to new applications and certain majority-ownership changes, for six months (extendable) [8]. This is unusually important for private investors: a greenfield business may be unable to get enrolled, an acquisition structured as a prohibited ownership change can be denied, and existing enrolled suppliers become more strategically valuable. (Single-source but CMS-documented; verify current status before any deal.)
• Enrollment, accreditation, surety bonds. Suppliers must enroll with Medicare, obtain third-party accreditation, and post a surety bond (generally $50,000 per supplier location) [8].
• Fraud and audit risk. DME is a fraud-prone category. Suppliers face the federal Anti-Kickback Statute, the False Claims Act, and retrospective audits and recoupments that can claw back already-collected revenue. Investigative reporting has documented repeated Medicare settlements at the largest operator, Lincare — a reminder that scale does not remove compliance risk [19].

---

8. Competitive dynamics and consolidation

The logic is: externally capped prices → scale is the only durable margin lever → relentless roll-up. When you can't raise prices, you win on purchasing power, route density, and billing automation — all of which reward size. Hence the consolidation visible in the federal data (firms down, revenue up) and the buy-and-build strategies of the leaders (AdaptHealth built via 100+ acquisitions; Rotech integrated 65+ in four years) [2][9][15].

But top-of-market M&A now hits an antitrust ceiling. Owens & Minor's $1.36 billion agreement to buy Rotech collapsed in mid-2025 over FTC-clearance concerns (with an $80 million breakup fee) — even as bolt-on roll-up of small suppliers continues largely unimpeded [10][15]. Owens & Minor then divested its legacy distribution business to Platinum Equity for $375 million and re-emerged as the home-medical pure-play Accendra Health [10].

Two other forces reshape the field:

• Direct-to-consumer resupply. Online sellers of CPAP masks and supplies are attacking the highest-margin annuity — the resupply stream — pressuring incumbents where they are most profitable.
• Supply and payer shocks. Device recalls (e.g., the industry-wide Philips CPAP/ventilator recall) and the loss of a large payer or capitation contract can reshuffle share quickly. Accendra, for instance, disclosed ~$322 million (12% of its home-medical revenue) of contracts being wound down in early 2026 — a concrete case of contract risk overwhelming favorable demographics [10].

---

9. Risks

The central risk is reimbursement/regulatory rate risk — the functional equivalent of interest-rate/cap-rate risk in real estate. In rough priority:

1. Reimbursement cuts. A new competitive-bidding round or fee-schedule reduction can compress revenue on a fixed cost base almost overnight. This is the dominant valuation variable [5][6].
2. Audit and recoupment. Retroactive denials and clawbacks can reverse revenue and cash already recognized [19].
3. Payer concentration / policy risk. Heavy Medicare/Medicaid dependence means federal budget and coverage decisions dominate; the growth of Medicare Advantage shifts negotiating leverage to plans, and losing a big contract hurts fast [10].
4. Interest-rate sensitivity — financial, not asset-valuation. Operators run ~2.5–3.0x leverage, often partly floating-rate; higher rates raise interest expense, cool acquisition math, and pressure over-levered private platforms at refinancing. (Note the difference from real estate: value here is set by EBITDA multiples on reimbursement-backed cash flow, not cap rates on rent [9].)
5. Residual-value / obsolescence risk on the fleet. Devices depreciate fast and can be stranded by technology shifts or recalls — residual value is a cost, not a profit source.
6. Patient attrition and compliance. A CPAP patient who abandons therapy (or fails a compliance test) can stop generating revenue before the supplier recovers its setup and device cost.
7. Direct-to-consumer margin erosion on the high-margin resupply annuity.
8. Labor, logistics, and supply-chain inflation against prices the operator cannot raise.

The upside of this profile: very low classic cyclicality — demand is demographic and non-discretionary — but very high policy cyclicality. Recessions barely matter; CMS rulemaking matters enormously.

---

10. How to invest, and the outlook

Public-market routes. The cleanest listed exposure is AdaptHealth (AHCO) — value it on EV/EBITDA and free-cash-flow yield (~$3.25B revenue, ~21% EBITDA margin, ~$219M FCF in 2025), not on FFO/AFFO, NAV, or dividend yield, which are category errors here [9]. Accendra Health (ACH) is a newer, second home-medical pure-play built on Apria/Byram [10]. Quipt (QIPT), Viemed (VMD), and Inogen (INGN) offer smaller, more specialized exposure (Viemed ventilator-heavy and profitable; Inogen more an oxygen-device maker than a rental play) [12][13][14]. Linde (LIN) gives only negligible, undisclosed exposure through Lincare — not a practical way to own the theme [11]. Across all of them, the key diligence question is whether reported EBITDA actually converts to free cash flow after equipment purchases, interest, denials, and working capital — and watch organic patient growth, resupply penetration, net leverage, and receivables/denial trends.

Private-market routes. Private equity is the dominant vehicle: buy-and-build roll-ups of small suppliers, where returns come from purchasing scale, route density, and multiple arbitrage financed with reimbursement-backed leverage. Direct ownership of a regional DME/respiratory company (thousands exist below the $41M SBA threshold) is a classic lower-middle-market entry — but underwrite on payer mix, transferable Medicare enrollment, referral density, and remaining reimbursable months on deployed equipment, not real-estate-style occupancy. Equipment/fleet lending against oxygen and sleep-device fleets is a niche credit exposure. And note that owning the warehouse a supplier leases is a real-estate deal (NAICS 531120), not exposure to the DME economics itself. The 2026 enrollment moratorium (Section 7) makes existing, compliant, transferable Medicare enrollments more valuable — and makes regulatory counsel essential before any transaction [8].

Outlook (forward-looking judgment). The base case is a structurally growing but policy-capped industry. The demographic tailwind (a 65+ population past 61 million and rising) and the shift of care into the home should keep unit demand and consolidation growing [16]. But margins and multiples will be governed by CMS, and the swing factors to watch are the 2028 competitive-bidding round (and whether it later expands to core oxygen/CPAP), the enrollment moratorium's duration, Medicare Advantage pricing, and each operator's cash conversion. Expect continued bolt-on roll-up, tougher top-of-market M&A after the Owens & Minor–Rotech failure, growing direct-to-consumer pressure on resupply margins, and the surviving public names trading as EBITDA-and-cash-flow compounders carrying a reimbursement-risk discount — never as yield or NAV vehicles.

The bottom line: 532283 is not a "buy equipment, charge rent" business. It is a healthcare-reimbursement network built on depreciating physical assets. The aging-demand tailwind is real; so are the government price ceiling and the balance-sheet risk. Long-run returns will be decided less by total market growth than by payer access, operational execution, and purchase-price discipline.

---

Sources

1. U.S. Census Bureau, 2022 NAICS — 532283 Home Health Equipment Rental (definition and exclusions). https://www.census.gov/naics/?input=532283&year=2022
2. U.S. Census Bureau, 2022 Economic Census, Sector 53 (EC2253BASIC) and concentration statistics — revenue $5,889,149K; 521 firms; CR4 65.8%, CR8 70.9%, CR20 78.1%, CR50 85.8%; HHI suppressed. https://data.census.gov/table/ECNBASIC2022.EC2253BASIC (2022; released 2024).
3. U.S. Census Bureau, County Business Patterns 2023, NAICS 532283 — 1,998 establishments; 25,952 employees; $1,510,426K annual payroll. https://data.census.gov/profile/532283_-_Home_Health_Equipment_Rental?codeset=naics~532283 (2023).
4. U.S. Small Business Administration, Table of Size Standards (13 CFR §121.201) — 532283 = $41.0M average annual receipts. https://www.sba.gov/document/support-table-size-standards (effective March 17, 2023).
5. Medicare Payment Advisory Commission (MedPAC), Payment Basics: Durable Medical Equipment — ~$7.5B Medicare DME spending, CY2022; 80%/20% payment; 13-month capped rental; 36-month oxygen cap. https://www.medpac.gov/wp-content/uploads/2022/10/MedPAC_Payment_Basics_23_DME_FINAL_SEC.pdf (rev. Oct 2023).
6. Centers for Medicare & Medicaid Services, DMEPOS Competitive Bidding Program — updates (contracts expired Dec 31, 2023; new round by Jan 1, 2028; announced categories and timeline). https://www.cms.gov/medicare/payment/fee-schedules/dmepos-competitive-bidding; https://www.cms.gov/newsroom/fact-sheets/durable-medical-equipment-prosthetics-orthotics-supplies-competitive-bidding-program-updates (2025–2026).
7. Medicare.gov, Oxygen equipment & accessories; DME capped-rental coverage. https://www.medicare.gov/coverage/oxygen-equipment-accessories; https://www.medicare.gov/coverage/durable-medical-equipment-dme-coverage (accessed 2026).
8. Centers for Medicare & Medicaid Services, Provider Enrollment Moratoria (Feb 27, 2026 DMEPOS moratorium; enrollment, accreditation, and $50,000 surety-bond requirements). https://www.cms.gov/medicare/enrollment-renewal/providers-suppliers/chain-ownership-system-pecos/provider-enrollment-moratoria (updated 2026).
9. AdaptHealth Corp., Form 10-K, FY2025 — revenue ~$3.245B; segment mix; ~33%/63% rental/sales; patient-equipment depreciation $341.3M; OCF $601.8M; FCF $219.4M; ~$1.75B gross debt. https://www.sec.gov/Archives/edgar/data/1725255/000162828026011213/ahco-20251231.htm (2026). Market-cap ~$1.3B (mid-2026): StockAnalysis/Macrotrends.
10. Owens & Minor / Accendra Health, Inc., Form 10-K, FY2025 — Patient Direct revenue $2.762B; Apria acquisition (2022, ~$1.6–1.7B); Rotech deal ($1.36B) terminated June 2025; distribution divested to Platinum Equity ($375M); contract wind-downs (~$322M). https://www.sec.gov/Archives/edgar/data/75252/000110465926018169/omi-20251231x10k.htm (2026).
11. Linde plc, 2025 Annual Report (consolidated sales $33.986B; Lincare not separately disclosed) and Lincare, About Lincare (700+ locations, 48 states). https://assets.linde.com/-/media/global/corporate/corporate/documents/investors/full-year-financial-reports/2025-annual-report-to-shareholders.pdf; https://www.lincare.com/en/why-lincare/about-lincare (2026).
12. Quipt Home Medical Corp., Form 10-K, FY2025 — revenue $245.4M; 175+ facilities. https://www.sec.gov/Archives/edgar/data/1540013/000110465925120879/qipt-20250930x10k.htm (2025).
13. Viemed Healthcare, Inc., Form 10-K, FY2025 — revenue $270.3M; net income $15.4M; 12,259 ventilator and 34,528 PAP patients. https://www.sec.gov/Archives/edgar/data/1729149/000172914926000009/vmd-20251231.htm (2026).
14. Inogen, Inc., Form 10-K, FY2025 — revenue $348.7M incl. $53.4M rental; rental gross margin 42.7%. https://www.sec.gov/Archives/edgar/data/1294133/000119312526082630/ingn-20251231.htm (2026).
15. Rotech Healthcare, Acquisitions (300+ locations, 65+ acquisitions) and Greenberg Traurig, Rotech $725M refinancing (Nov 2025). https://www.rotech.com/acquisitions/; https://www.gtlaw.com/en/news/2025/11/press-releases/greenberg-traurig-represents-rotech-healthcare-inc-in-connection-with-the-refinancing-of-its-%24725-million-senior-secured-credit-facilities (2025).
16. U.S. Census Bureau, Older Adults Outnumber Children… — 65+ population 61.2M / 18.0% in 2024, +13% since 2020. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html (2025).
17. CDC/NCHS, Chronic Obstructive Pulmonary Disease in Adults: United States, 2023 — COPD prevalence by age; 5th-leading cause of death; ~$24B costs. https://www.cdc.gov/nchs/products/databriefs/db529.htm (2025).
18. Prevalence of Obstructive Sleep Apnea in the United States: 2024 Model Estimate — ~83.7M adults (modeled). https://pubmed.ncbi.nlm.nih.gov/40957495/ (2025).
19. ProPublica, Lincare Medicare lawsuits and settlements over oxygen equipment. https://www.propublica.org/article/lincare-medicare-lawsuit-settlements-oxygen-equipment (2024–2025).
20. Nareit, Funds From Operations (FFO) and Adjusted FFO (AFFO); IRS, Instructions for Form 1120-REIT (REIT distribution rule) — reference for why REIT metrics do not apply here. https://www.reit.com/glossary/funds-operation-ffo; https://www.irs.gov/instructions/i1120rei (accessed 2026).